← All trials
NCT04439695
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 23, 2020
- Primary completion
- Oct 24, 2020
- Completion date
- Jan 30, 2021
- First posted
- Jun 19, 2020
- Last posted
- Jun 19, 2020
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kentucky BioProcessing, Inc.Lead sponsor
- Meridien ResearchOverall official - principal investigator
- Kentucky BioProcessing, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.